Novartis Investigative Site
Gaziantep 27310
0 studies enrolling now · 11 studies all time
What they study most
Acute Gout, Advanced NET of GI Origin, Advanced NET of Lung Origin, Ankylosing Spondylitis, Cardiovascular Disease, Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Moderate and Severe Plaque Psoriasis, Moderate to Severe Palmoplantar Psoriasis, Neoplasms, Gastrointestinal Tract, Neuroendocrine Tumors, Relapsing Forms of Multiple Sclerosis
Studies at this site
- LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
- This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). — Completed
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines — Completed
- Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
- Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
- A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis — Completed
- Extension in AS: Sustainability of Benefits, Safety and Tolerability — Completed
- Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis — Completed
- 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis — Completed
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
- Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients — Completed